[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rapid-arrhythmia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rapid-arrhythmia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100598121","clinical-study-on-the-safety-and-efficacy-of-a-new-magnetic-navigation-radiofrequency-ablation-catheter-for-rapid-arrhythmia-100598121",false,"NCT07067372","Clinical Study on the Safety and Efficacy of a New Magnetic Navigation Radiofrequency Ablation Catheter for Rapid Arrhythmia","Clinical Study on the Safety and Efficacy of FireMagic™ Magbot Ablation Catheter for Rapid Arrhythmia","Rapid arrhythm","Inclusion Criteria:\n\n* 1\\) Patients aged 18 to 80 years old, with no gender restrictions; 2) Patients clinically diagnosed with paroxysmal atrial fibrillation or symptomatic supraventricular tachycardia: i. For patients with paroxysmal atrial fibrillation, atrial fibrillation was recorded by surface electrocardiogram or Holter monitoring (including single-lead electrocardiogram) within one year prior to enrolment; ii. For patients with symptomatic supraventricular tachycardia, PSVT (AVNRT or AVRT) was recorded by electrocardiogram, Holter monitoring, or electrophysiological examination; 3) Patients who have not responded adequately to or are intolerant of at least one antiarrhythmic drug, or who are willing to undergo ablation surgery without prior medication; 4) Patients who fully understand the treatment plan, voluntarily sign the informed consent form, and are willing to undergo the examinations, surgery, and follow-up required by the plan.\n\nExclusion Criteria:\n\n* 1\\) Left atrial thrombus (not applicable for PSVT); 2) Left atrial anteroposterior diameter ≥55 mm (not applicable for PSVT); 3) Left ventricular ejection fraction (LVEF) ≤40%; 4) Previous history of atrial septal defect repair or atrial myxoma (not applicable for PSVT); 5) Presence of active implantable devices (e.g., pacemaker, ICD, etc.); 6) NYHA functional class III-IV; 7) History of cerebrovascular disease within the past 6 months (including cerebral haemorrhage, stroke, transient ischaemic attack); 8) History of cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, atrial or ventricular incision); 9) Acute or severe systemic infection; 10) Patients with severe liver or kidney disease, malignant tumours, or end-stage diseases, or those whom the investigator believes may interfere with the treatment, evaluation, or compliance of this trial; 11) Patients with a significant tendency to bleed, hypercoagulable states, or severe haematological disorders.","ALL","18 Years","80 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","Clinical study on the safety and efficacy of FireMagic™ Magbot Ablation Catheter for rapid arrhythmia",[28,29,30],"Rapid Arrhythmia","PFA","Symptomatic Supraventricular Tachycardia",[32,33],"Paroxysmal atrial fibrillation","Symptomatic supraventricular tachycardia","NOT_YET_RECRUITING","2025-07-14",{"date":37,"type":38},"2025-07-16","ACTUAL",{"date":40,"type":22},"2025-12-31",{"date":42,"type":22},"2028-12-31",{"name":44,"class":45},"Shanghai MicroPort EP MedTech Co., Ltd.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":67,"locationsCount":4},"100595476","safety-and-efficacy-study-of-the-first-domestically-produced-firemagic-precisense-3d-microelectrode-ablation-catheter-therapy-for-rapid-arrhythmia-with-tissue-temperature-measurement-function-100595476","NCT07032948","Safety and Efficacy Study of the First Domestically Produced FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter Therapy for Rapid Arrhythmia With Tissue Temperature Measurement Function","1\\. Inclusion Criteria\n\n1. Patient age between 18 and 75 years old, male or non-pregnant female;\n2. Confirmed diagnosis of supraventricular tachycardia or atrial fibrillation requiring catheter radiofrequency ablation surgery;\n3. Signed informed consent form approved by the ethics committee;\n4. Willingness to undergo follow-up and evaluation as required by the protocol.\n\n2\\. Exclusion Criteria Include:\n\n1. Exclusion criteria for atrial fibrillation patients:\n\n   Patients should not participate in this study if any of the following conditions apply:\n   * Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%;\n   * Left atrial thrombus;\n   * History of atrial septal repair or atrial myxoma;\n   * History of cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack);\n   * Cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision);\n   * Acute or severe systemic infection;\n   * Severe liver or kidney disease;\n   * Significant bleeding tendency or haematological disorders;\n   * Patients with other conditions deemed inappropriate for participation in this trial by the investigators.\n2. Exclusion criteria for patients with ventricular tachycardia and supraventricular tachycardia:\n\nPatients should not participate in this study if any of the following conditions apply:\n\n* Left atrial size ≥50 mm and left ventricular ejection fraction ≤40%;\n* History of atrial septal defect repair or atrial myxoma;\n* Patients with cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack);\n* Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision);\n* Patients with acute or severe systemic infection;\n* Patients with severe liver or kidney disease;\n* Patients with a significant tendency to bleed or haematological disorders;\n* Patients with other conditions deemed by the investigator to be unsuitable for participation in this trial.","75 Years",{"count":55,"type":22},300,[25],"This project aims to evaluate the safety, efficacy, and cost-effectiveness of using FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter to treat rapid arrhythmias.",[28,59,60],"Atrial Fibrillation (AF)","Paroxysmal Supraventricular Tachycardia (PSVT)","2025-06-23",{"date":63,"type":38},"2025-06-24",{"date":65,"type":22},"2025-08-31",{"date":65,"type":22},{"name":44,"class":45}]